Please Scroll Down to See Forums Below 
c24k
New member
Hello. This is just an effort by me (c24k) to give back to this awesome community. I haven't seen anything like this yet, figured it would be a sticky. I'm making a quick reference guide to the most common AAS (Androgenic Anabolic Steroids), in an attempt to minimize your googling time or whatever you use. This is just a quick reference, it DOES NOT contain 100% everything you need to know its nothing more than a quick reference 
***DISCLAIMER***
I AM NOT A MEDICAL DOCTOR. ANYTHING I SAY IS FOR ENTERTAINMENT AND INFORMATIONAL PURPOSES ONLY. ALWAYS CONSULT A PHYSCIAN OR A FAMILY DOCTOR.
*****************************************************************
NANDROLONE DECANOATE
Deca-Durabolin, Kabolin (CAN)
Drug Classes
Anabolic Steroid
Hormone
Theraputic actions
Testosterone analogue; promotes body tissue-building processes and reverses catabolic or tissue depleting processes; increases Hgb and red cell mass.
Indications
Injection - 100, 200 mg/ml
Pharmacokinetics
Metabolism: Hepatic; T 1/2; Unknown
Distribution: Crosses placenta; enters breast milk
Excretion: Unknown
Adverse Effects
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agnets with anabolic steriods.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
OXANDROLONE
Oxandrin, Anavar
Drug Classes
Anabolic Steroid
Hormone
Therapeutic Actions
Testosterone analogue; promotes body tissue-building processes and reverses catabolic or tissue depleting processes; increases Hgb and red cell mass.
Indications
Tablets - 2.5 mg (Oxandrin)
Tablets - 50 mg (Anavar)
Pharmacokinetics
Metabolism: Hepatic; T 1/2; 9 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Adverse Effects
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agents with anabolic steroids.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
OXYMETHOLONE
Anadrol-50, Anapolon 50 (CAN)
Drug Classes
Anabolic Steroid
Hormone
Indications
Tablets - 50 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2; 9 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Adverse Effects
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agents with anabolic steroids.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
STANOZOLOL
Winstrol
Drug Classes
Anabolic Steroid
Hormone
Therapeutic Actions
Testosterone analogue; promotes body tissue-building processes and reverses catabolic or tissue depleting processes; increases Hgb and red cell mass.
Indications
Tablets - 10 mg
Injection - 50 mg/ml
Pharmacokinetics
Metabolism: Hepatic; T 1/2; 9 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Adverse Effects
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agents with anabolic steroids.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
Testosterone Cypionate (long-acting); Testosterone Enanthate (long-acting)
Drug Classes
Androgen
Hormone
Therapeutic Actions
Primary natural androgen; responsible for growth and development of male sex organs and the maintenance of secondary sex characteristics; administration of exogenous testosterone increases the retention of nitrogen, sodium, potassium phosphorus; decreases urinary excretion of calcium; increases protein anabolism and decreases protein catabolism; stimulates the production of red blood cells
Indications
Testosterone Enanthate Injection - 200 mg/ml
Testosterone Cypionate Injection - 100, 200 mg/ml; Buggal system 30 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 10-100 min; up to 8 days cypionate
Distribution: Crosses placenta; may enter breast milk
Excreation: Urine and feces
Adverse Effects
Drug-food. Decreased metabolism and risk of toxic effects if combined with grapefruit juice; avoid this combination
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
---------------------------------------------------------------------------------------------------------------------------------------------------------
POST CYCLE!!!!!!!!!!!!!!!!!!!!!!
Anastrozole
Arimidex
Drug Class
Antiestrogen
Therapeutic Actions
Selective nonsteroidal aromatase inhibitor that significantly reduces serum estradiol levels with no significant effect on adrenocortical steroids or aldosterone.
Indications
Contraindications and Cautions
Tablets - 1 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 50 hrs
Distribution: Crosses placenta; enters breast milk
Excretion: Feces and Urine
Adverse Effects
Clomiphene CITRATE
Clomid, Milophene, Serophene
Drug Classes
Hormone
Fertility Drug
Therapeutic Actions
Binds to estrogen receptors, decreasing the number of available estrogen receptors, which gives the hypothalmus the false signal to increase FSH and LH secretion, resulting in ovarian stimulation.
Indications
Tablets - 50 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 5 days
Distribution: Crosses placenta
Excretion: Feces
Adverse Effects
Drug-lab test. Increased levels of serum thyroxine, thyroxine-binding globulin
Tamoxifen CITRATE
Apo-Tamox (CAN), Nolvadex, Novo-Tamoxifen (CAN), Tamofen (CAN), Tamone (CAN)
Drug Class
Antiestrogen
Therapeutic Actions
Potent antiestrogen effects: Competes with estrogen for binding sites in target tissues, such as the breast.
Indications
Tablets - 10, 20 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 7-14 days
Distribution: Crosses placenta; may enter breast milk
Excretion: Feces
Adverse Effects
Drug-drug. Increased risk of bleeding with oral anticoagulants. Increased serum levels with bromocriptine. Increased risk of thromboembolic events if given with cytotoxic agents.
Drug-food. Decreased metabolism and risk of toxic effects if combined with grapefruit juice; avoid this combination
Drug-lab test. Possible increase in calcium levels, T4 levels without hyperthyroidism
Bromocriptine mesylate
Bromocriptin, Apo-Bromocriptine (CAN), Parlodel, Parlodel SnapTabs
Drug Classes
Antiparkinsonian
Dopamine receptor agonist
Semisythetic ergot derivative
Therapeutic Actions
Parkinsonism: Acts as an agonist directly on postsynaptic dopamine receptors of neurons in the brain, mimicking the effects of the neurotransmitter dopamine, which is deficient in parkinsonism. Unlike levodopa, bromocriptine does not require biotransformation by the nigral neurons that are deficient in parkinsonism patients; thus, bromocriptine may be effective when levodopa has begun to lose its efficacy.
Hyperprolactinemia: Acts directly on post-synaptic dopamine receptors of the prolactin-secreting cells in the anterior pituitary, mimicking the effects of prolactin inhibitory factor, inhibiting the release of prolactin and galactorrhea. Also restores normal ovulatory menstrual cycles in patients with amenorrhea or galactorrhea, and inhibits the release of growth hormone in patients with acromegaly.
Indications
Capsules - 5 mg ; Tablets - 2.5 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 3 hr (initial phase), 45-50 hrs (terminal phase)
Excretion: Bile
Adverse Effects
Drug-drug. Increased serum bromocriptine levles and increased pharmacologic and toxic effects with erythromycin. Decreased effectiveness with phenothiazines for treatment of prolactin-secreting tumors. Increased bromocriptine adverse effects if cominded with sympathomimetics
Note: I fail to see why this is being marketed by certain 'sites' as an anti-estrogen. I do not recommend that you even take this for an Anti-E.
Toremifene
Fareston
Drug Classes
Estrogen Receptor modulator
Antineoplastic
Indications
Treatment of advanced breast cancer in post-menopausal women with estrogen receptor-positive and estrogne receptor-negative breast cancer cell lines.
Contraindications and Cautions
Tablets - 60 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 5-6 days
Distribution: Crosses Placenta; enters breast milk
Excretion: Feces
Adverse Effects
Drug-drug. Increased risk of bleeding if taken with anticoagulants
Letrozole
Femara
Drug Classes
Antiestrogen
Aromatase inhibitor
Therapeutic Actions
Inhibits the conversion of androgens to estrogens by the aromatase enzyme system (in post menopausal women, the aromatase system is the main source of estrogens); reduces estrogen levels in all tissues, including tumors.
Indications
Treatment of advanced breast cancer in postmenopausal women as a first-line treatment and with disease progression following traditional antiestrogen therapy
Contraindications and Cautions
Metabolism: Hepatic; T 1/2: 2 days
Distribution: Crosses placenta; may enter breast milk
Excretion: Urine
Adverse Effects
***DISCLAIMER***
I AM NOT A MEDICAL DOCTOR. ANYTHING I SAY IS FOR ENTERTAINMENT AND INFORMATIONAL PURPOSES ONLY. ALWAYS CONSULT A PHYSCIAN OR A FAMILY DOCTOR.
*****************************************************************
NANDROLONE DECANOATE
Deca-Durabolin, Kabolin (CAN)
Drug Classes
Anabolic Steroid
Hormone
Theraputic actions
Testosterone analogue; promotes body tissue-building processes and reverses catabolic or tissue depleting processes; increases Hgb and red cell mass.
Indications
- Management of anemia to renal insufficiency
- Contraindicated with known sensitivity to nandrolone or anabolic steroids; prostate or breast cancer in males; BPH; breast cancer (females); pituitary insufficiency; MI (contraindicated because of effects on cholesterol); nephrosis liver disease; hypercalcemia; prenancy; lactation
- Use cautiously with cardiac, renal, or liver disease; epilepsy; migraines; diabetes; seizure disorders.
Injection - 100, 200 mg/ml
Pharmacokinetics
Metabolism: Hepatic; T 1/2; Unknown
Distribution: Crosses placenta; enters breast milk
Excretion: Unknown
Adverse Effects
- CNS: Excitation, insomnia, chills, toxic confusion
- Endocrine: Virilization; in prepubertal males, phallic enlargement, hirsustism, increased skin pigmentation; in postpubertal males, inhibition of testicular function, gynecomastia, testicular atrophy, priapism, baldness epididymitis, change in libidio; In Females, hirsustism, hoarseness, deepening of the voice, clitoral enlargement, menstrual irregularities, baldness; decreased glucose tolerance
- GI: Hepatoxicity, peliosis, hepatitis with life-threatening liver failure or intra-abdominal hemorrage; liver cell tumors, sometimes malignant; nausea, vomiting, diarrhea, abdominal fullness, loss of appetite, burning of the tongue
- GU: Increased risk of prostatic hypertrophy, carcinoma in geriatric patients
- Hematologic: Blood lipid changes (increased risk of atherosclerosis); iron-deficiency anemia, hypercalcemia, altered serum cholesterol levels; retention of sodium, chloride, water, potassium, phosphates and calcium.
- Other: Acne, premature closure of the epiphyses
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agnets with anabolic steriods.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
OXANDROLONE
Oxandrin, Anavar
Drug Classes
Anabolic Steroid
Hormone
Therapeutic Actions
Testosterone analogue; promotes body tissue-building processes and reverses catabolic or tissue depleting processes; increases Hgb and red cell mass.
Indications
- Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, trauma
- Offset protein catabolism associated with prolonged use of corticosteroids
- Orphan drug uses: Short stature associated with Turner Syndrome, HIV wasting syndrome, and HIV-associated muscle weakness
- Unlabeled use: Alcoholic hepatitis
- Contraindicated with known sensitivity to nandrolone or anabolic steroids; prostate or breast cancer in males; BPH; breast cancer (females); pituitary insufficiency; MI (contraindicated because of effects on cholesterol); nephrosis liver disease; hypercalcemia; pregnancy; lactation
- Use cautiously with CHF; cardiac, renal or liver disease, epilepsy, migraines, diabetes.
Tablets - 2.5 mg (Oxandrin)
Tablets - 50 mg (Anavar)
Pharmacokinetics
Metabolism: Hepatic; T 1/2; 9 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Adverse Effects
- CNS: Excitation, insomnia, chills, toxic confusion
- Endocrine: Virilization; in prepubertal males, phallic enlargement, hirsustism, increased skin pigmentation; in postpubertal males, inhibition of testicular function, gynecomastia, testicular atrophy, priapism, baldness epididymitis, change in libidio; In Females, hirsustism, hoarseness, deepening of the voice, clitoral enlargement, menstrual irregularities, baldness; decreased glucose tolerance
- GI: Hepatoxicity, peliosis, hepatitis with life-threatening liver failure or intra-abdominal hemorrhage; liver cell tumors, sometimes malignant; nausea, vomiting, diarrhea, abdominal fullness, loss of appetite, burning of the tongue
- GU: Increased risk of prostatic hypertrophy, carcinoma in geriatric patients
- Hematologic: Blood lipid changes (increased risk of atherosclerosis); iron-deficiency anemia, hypercalcemia, altered serum cholesterol levels; retention of sodium, chloride, water, potassium, phosphates and calcium.
- Other: Acne, premature closure of the epiphyses
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agents with anabolic steroids.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
OXYMETHOLONE
Anadrol-50, Anapolon 50 (CAN)
Drug Classes
Anabolic Steroid
Hormone
Indications
- Anemias caused by deficient red cell production
- Acquired or congenital aplastic anemia
- Myelofibrosis and hypoplastic anemias due to myelotoxic drugs
- Contraindicated with known sensitivity to nandrolone or anabolic steroids; prostate or breast cancer in males; BPH; breast cancer (females); pituitary insufficiency; MI (contraindicated because of effects on cholesterol); nephrosis liver disease; hypercalcemia; pregnancy; lactation
- Use cautiously with CHF; cardiac, renal or liver disease, epilepsy, migraines, diabetes.
Tablets - 50 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2; 9 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Adverse Effects
- CNS: Excitation, insomnia, chills, toxic confusion
- Endocrine: Virilization; in prepubertal males, phallic enlargement, hirsustism, increased skin pigmentation; in postpubertal males, inhibition of testicular function, gynecomastia, testicular atrophy, priapism, baldness epididymitis, change in libidio; In Females, hirsustism, hoarseness, deepening of the voice, clitoral enlargement, menstrual irregularities, baldness; decreased glucose tolerance
- GI: Hepatoxicity, peliosis, hepatitis with life-threatening liver failure or intra-abdominal hemorrage; liver cell tumors, sometimes malignant; nausea, vomiting, diarrhea, abdominal fullness, loss of appetite, burning of the tongue
- GU: Increased risk of prostatic hypertrophy, carcinoma in geriatric patients
- Hematologic: Blood lipid changes (increased risk of atherosclerosis); iron-deficiency anemia, hypercalcemia, altered serum cholesterol levels; retention of sodium, chloride, water, potassium, phosphates and calcium.
- Other: Acne, premature closure of the epiphyses
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agents with anabolic steroids.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
STANOZOLOL
Winstrol
Drug Classes
Anabolic Steroid
Hormone
Therapeutic Actions
Testosterone analogue; promotes body tissue-building processes and reverses catabolic or tissue depleting processes; increases Hgb and red cell mass.
Indications
- Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, trauma
- Offset protein catabolism associated with prolonged use of corticosteroids
- Orphan drug uses: Short stature associated with Turner Syndrome, HIV wasting syndrome, and HIV-associated muscle weakness
- Unlabeled use: Alcoholic hepatitis
- Contraindicated with known sensitivity to nandrolone or anabolic steroids; prostate or breast cancer in males; BPH; breast cancer (females); pituitary insufficiency; MI (contraindicated because of effects on cholesterol); nephrosis liver disease; hypercalcemia; pregnancy; lactation
- Use cautiously with CHF; cardiac, renal or liver disease, epilepsy, migraines, diabetes.
Tablets - 10 mg
Injection - 50 mg/ml
Pharmacokinetics
Metabolism: Hepatic; T 1/2; 9 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Adverse Effects
- CNS: Excitation, insomnia, chills, toxic confusion
- Endocrine: Virilization; in prepubertal males, phallic enlargement, hirsustism, increased skin pigmentation; in postpubertal males, inhibition of testicular function, gynecomastia, testicular atrophy, priapism, baldness epididymitis, change in libidio; In Females, hirsustism, hoarseness, deepening of the voice, clitoral enlargement, menstrual irregularities, baldness; decreased glucose tolerance
- GI: Hepatoxicity, peliosis, hepatitis with life-threatening liver failure or intra-abdominal hemorrage; liver cell tumors, sometimes malignant; nausea, vomiting, diarrhea, abdominal fullness, loss of appetite, burning of the tongue
- GU: Increased risk of prostatic hypertrophy, carcinoma in geriatric patients
- Hematologic: Blood lipid changes (increased risk of atherosclerosis); iron-deficiency anemia, hypercalcemia, altered serum cholesterol levels; retention of sodium, chloride, water, potassium, phosphates and calcium.
- Other: Acne, premature closure of the epiphyses
Drug-drug. Potentiation of oral anticoagulants with anabolic steroids. Decreased need for insulin, oral hypoglycemia agents with anabolic steroids.
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
Testosterone Cypionate (long-acting); Testosterone Enanthate (long-acting)
Drug Classes
Androgen
Hormone
Therapeutic Actions
Primary natural androgen; responsible for growth and development of male sex organs and the maintenance of secondary sex characteristics; administration of exogenous testosterone increases the retention of nitrogen, sodium, potassium phosphorus; decreases urinary excretion of calcium; increases protein anabolism and decreases protein catabolism; stimulates the production of red blood cells
Indications
- Testosterone pellets and testosterone enanthate only: Replacement therapy in hypogonadism - primary hypogonadism, delayed puberty (men)
- Testosterone enanthate only: Inoperable breast cancer
- Testosterone enanthate only: Metastatic mammary cancer
- Contraindicated with known sensitivity to androgens; prostate or breast cancer in men; pregnancy; lactation; serious cardiac, hepatic or renal disease. Testoderm contraindicationed for use in women.
- Use caustiously with MI.
Testosterone Enanthate Injection - 200 mg/ml
Testosterone Cypionate Injection - 100, 200 mg/ml; Buggal system 30 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 10-100 min; up to 8 days cypionate
Distribution: Crosses placenta; may enter breast milk
Excreation: Urine and feces
Adverse Effects
- CNS: Dizziness, headache, sleep disorders, fatigue, tremor, sleeplessness, generalized paresthesia, sleep apnea syndrome, CNS hemorrhage
- Dermatologic: Rash, dermatitis, anaphylactoid reactions
- Endrocrine: Androgenic effects (acne, edema, mild hirsutism, decrease in breast size, deepening of the voice, oily skin or hair, weight gain, clitoral hypertrophy, or testicular atrophy), hypoestrogenic effects (flushing, sweating, vaginitis, nervousness, emotional lability)
- GI: Nausea, hepatic dysfunction; hepatocellular carcinoma
- GU: Fluid retention, decreased urinary output
- Hematologic: Polycythemia; leukopenia; hypercalcemia; altered serum cholesterol levels; retention of sodium, chloride, water, potassium, phosphates, and calcium
- Other: Chills, premature closure of the epiphyses
Drug-food. Decreased metabolism and risk of toxic effects if combined with grapefruit juice; avoid this combination
Drug-lab test. Altered glucose tolerance tests. Decrease in thyroid function tests, which may persist for 2-3 wk after stopping therapy (cycle). Increased creatinine, creatinine clearance, which may last for 2 wk after therapy (cycle).
---------------------------------------------------------------------------------------------------------------------------------------------------------
POST CYCLE!!!!!!!!!!!!!!!!!!!!!!
Anastrozole
Arimidex
Drug Class
Antiestrogen
Therapeutic Actions
Selective nonsteroidal aromatase inhibitor that significantly reduces serum estradiol levels with no significant effect on adrenocortical steroids or aldosterone.
Indications
- Treatment of advanced breast cancer in post menopausal women with disease progression following Tamoxifen therapy
- First-line treatment of postmenopausal women with hormone receptro positive or hormone receptor unknown locally advanced or metastatic breast cancer
- Adjuvant treatment of postmenopausal women with hormone-receptor positive early breast cancer
Contraindications and Cautions
- Contraindicated with allergy to anastrazole, pregnancy, lactation.
- Use cautiously with hepatic or renal impairment, high cholesterol states.
Tablets - 1 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 50 hrs
Distribution: Crosses placenta; enters breast milk
Excretion: Feces and Urine
Adverse Effects
- CNS: Depression, light-headedness, dizziness, asthenia
- Dermatologic: Hot flashes, rash
- GI: Nausea, vomiting, food distaste, dry mouth, pharyngitis
- GU: Vaginal bleeding, Vaginal pain, UTIs (Urinary Tract Infection)
- Other: Peripheral edema, bone pain, back pain; increased HDL, LDL levels
Clomiphene CITRATE
Clomid, Milophene, Serophene
Drug Classes
Hormone
Fertility Drug
Therapeutic Actions
Binds to estrogen receptors, decreasing the number of available estrogen receptors, which gives the hypothalmus the false signal to increase FSH and LH secretion, resulting in ovarian stimulation.
Indications
- Treatment of ovarian failure in patients with normal liver function and normal endogenous estrogen levels, whose partners are fertile and potent
- Unlabeled use: Treatment of male infertility
- Contraindicated with known sensitivity to Clomiphene, liver disease, abnormal bleeding of undetermined origin, ovarian cyst, uncontrolled thryroid or adrenal dysfunction, organic intracranial lesions, pregnancy
- Use cautiously with lactation
Tablets - 50 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 5 days
Distribution: Crosses placenta
Excretion: Feces
Adverse Effects
- CNS: Visual symptoms (blurring, spots, flashes), nervousness, insomnia, dizziness, light-headedness
- CV: Vasomotor flushing
- GI: Abdominal discomfort, distention, bloating, nausea, vomiting
- GU: Uterine bleeding, ovarian enlargement, ovarian overstimulation, birth defects in resulting pregnancies
- Other: Breast tenderness
Drug-lab test. Increased levels of serum thyroxine, thyroxine-binding globulin
Tamoxifen CITRATE
Apo-Tamox (CAN), Nolvadex, Novo-Tamoxifen (CAN), Tamofen (CAN), Tamone (CAN)
Drug Class
Antiestrogen
Therapeutic Actions
Potent antiestrogen effects: Competes with estrogen for binding sites in target tissues, such as the breast.
Indications
- Treatment of metastatic breast cancer in women and men; in premenopausal women with metastatic breast cancer, Tamoxifen is an alternative to oophorectomy or ovarian irradiation
- Treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation
- Treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.
- Reduction in risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation
- Reduction in occurrence of contralateral breast cancer in patients receiveing adjuvant Tamoxifen therapy for breast cancer
- Reduction in incidence of breast cancer in women at high risk for breast cancer
- Unlabeled uses: Treatment of mastalgia' useful for decresating size and pain of gynecomastia; treatment of McCune-Albright syndrome and precocious puberty in girls 2-10 yr
- Contraindicated with allergy to Tamoxifen, pregnancy, lactation, women who require concomitant coumarin-type anticoagulatn therapy or in women with a history of DVT or PE.
- Use cautiously in women with a history of thromboembolic events
Tablets - 10, 20 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 7-14 days
Distribution: Crosses placenta; may enter breast milk
Excretion: Feces
Adverse Effects
- CNS: Depression, light-headedness, dizziness, headache, corneal opacity, decreased visual acuity, retinopathy, stroke
- Dermatologic: Hot flashes, rash, Stevens-Johnson syndrome
- GI: Nausea, vomiting, food distaste, alterations in liver enzymes
- GU: Vaginal bleeding, vaginal discharge, menstrual irregularities, pruritus vulvae, endometrial cancer, uterine sarcoma
- Hematologic: Hypercalcemia, especialy with bone metastases, thrombocytopenia, leukopenia, anemia, DVT
- Other: Peripheral edema; increased bone and tumor pain and local disease (initially seen with a good tumor response, usually subsides); cancer in animal studies, chanes in LFTs, PE
Drug-drug. Increased risk of bleeding with oral anticoagulants. Increased serum levels with bromocriptine. Increased risk of thromboembolic events if given with cytotoxic agents.
Drug-food. Decreased metabolism and risk of toxic effects if combined with grapefruit juice; avoid this combination
Drug-lab test. Possible increase in calcium levels, T4 levels without hyperthyroidism
Bromocriptine mesylate
Bromocriptin, Apo-Bromocriptine (CAN), Parlodel, Parlodel SnapTabs
Drug Classes
Antiparkinsonian
Dopamine receptor agonist
Semisythetic ergot derivative
Therapeutic Actions
Parkinsonism: Acts as an agonist directly on postsynaptic dopamine receptors of neurons in the brain, mimicking the effects of the neurotransmitter dopamine, which is deficient in parkinsonism. Unlike levodopa, bromocriptine does not require biotransformation by the nigral neurons that are deficient in parkinsonism patients; thus, bromocriptine may be effective when levodopa has begun to lose its efficacy.
Hyperprolactinemia: Acts directly on post-synaptic dopamine receptors of the prolactin-secreting cells in the anterior pituitary, mimicking the effects of prolactin inhibitory factor, inhibiting the release of prolactin and galactorrhea. Also restores normal ovulatory menstrual cycles in patients with amenorrhea or galactorrhea, and inhibits the release of growth hormone in patients with acromegaly.
Indications
- Treastment of postencephalitic or idiopathic Parkinson's Disease; may provide additional benefit in patients currently maintained on optimal dosages of levodopa with or without carbidopa, beginning to deteriorate or develop tolerance to levodopa, and experiencing "end of dose failure" on levodopa dosage and decrease the dyskinesias and "on-off" phenomenon associated with long-term levodopa therapy.
- Short-term treatment of amenorrhea or galactorrhea associated with hyperprolactinemia due to various etiologies, excluding demonstrable pituitary tumors
- Treatment of hyperprolactinemia associated with pituitary adenomas to reduce elevated prolactin levels, cause shrinkage of macroprolactinomas; may be used to reduce the tumor mass before surgery
- Female infertility associated with hyperprolactinemia in the absecne of a demonstrable pituitary tumor
- Acromegaly; used alone or with pituitary irradiation or surgery to reduce serum growth hormone level
- Unlabeled uses: Neuroleptic malignant syndrome, cocaine addiction, cyclical mastalgia
- Contraindicated with hypersensitivity to bromocriptine or any ergot alkaloid; severe ischemic heart disease or peripheral vascular disease; pregnancy, lactation.
- Use cautiously with history of MI with residual arrhythmias (artial, nodal, or ventricular); renal or hepatic disease, history of peptic ulcer (fatal bleeding ulcers have occured in patients with acromegaly treated with bromocriptine).
Capsules - 5 mg ; Tablets - 2.5 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 3 hr (initial phase), 45-50 hrs (terminal phase)
Excretion: Bile
Adverse Effects
- CNS: Dizziness, fatigue, light-headedness, nasal congestion, drowsiness, CSF rhinorrhea in patients who have had transsphenoidal surgery, pituitary radiation
- CV: Hypotension
- GI: Nausea, vomiting, abdominal cramps, constipation, diarrhea, headache,
- CNS: Headache, dizziness, nausea, vomiting, fatigue, syncope
- CV: Hyptension
- GI: Diarrhea, cramps
- CNS: Nasal Congestion, digital vasospasm, drowsiness
- CV: Exacerbation of Raynaud's syndrome, orthostatic hypotension
- GI: Nausea, constipation, anorexia, indigestion, dry mouth, vomiting, GI bleeding
- CNS: Abnormal involuntary movements, hallucinations, confusion, "on-off: phenomenon, dizziness, drowsiness, faintness, asthenia, visual disturbance, ataxia, insomnia, depression, vertigo
- CV: Hypotension, shortness of breath
- GI: Nausea, vomiting, abdominal discomfort, constipation
Drug-drug. Increased serum bromocriptine levles and increased pharmacologic and toxic effects with erythromycin. Decreased effectiveness with phenothiazines for treatment of prolactin-secreting tumors. Increased bromocriptine adverse effects if cominded with sympathomimetics
Note: I fail to see why this is being marketed by certain 'sites' as an anti-estrogen. I do not recommend that you even take this for an Anti-E.
Toremifene
Fareston
Drug Classes
Estrogen Receptor modulator
Antineoplastic
Indications
Treatment of advanced breast cancer in post-menopausal women with estrogen receptor-positive and estrogne receptor-negative breast cancer cell lines.
Contraindications and Cautions
- Contraindicated with allergy to toremifene; pregnancy, lactation
- use cautiously with history of hypercalcemia, liver dysfunction
Tablets - 60 mg
Pharmacokinetics
Metabolism: Hepatic; T 1/2: 5-6 days
Distribution: Crosses Placenta; enters breast milk
Excretion: Feces
Adverse Effects
- CNS: Depression, light-headedness, dizziness, headache, hallucinations, vertigo
- Dermatologic: Hot flashes, skin rash
- GI: Nausea, vomiting, food distaste
- GU: Vaginal bleeding, vaginal discharge
- Other: Peripheral edema, hypercalcemia, cataracts, sweating
Drug-drug. Increased risk of bleeding if taken with anticoagulants
Letrozole
Femara
Drug Classes
Antiestrogen
Aromatase inhibitor
Therapeutic Actions
Inhibits the conversion of androgens to estrogens by the aromatase enzyme system (in post menopausal women, the aromatase system is the main source of estrogens); reduces estrogen levels in all tissues, including tumors.
Indications
Treatment of advanced breast cancer in postmenopausal women as a first-line treatment and with disease progression following traditional antiestrogen therapy
Contraindications and Cautions
- Contraindicated with allergy to letrozole, pregnancy.
- Use cautiously with hepatic impairment, lactation
Metabolism: Hepatic; T 1/2: 2 days
Distribution: Crosses placenta; may enter breast milk
Excretion: Urine
Adverse Effects
- CNS: Depression, headache, fatigue
- Dermatologic: Alopecia, hot flashes, rash
- GI: Nausea, GI upset, elevated liver enzymes
- Other: Peripheral edema; arthalgia
Last edited:
